Loading…
Loading…
IDXG does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IDXG and 80,000+ other tickers.
See exactly how IDXG's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IDXG and 80,000+ other tickers.
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select…
PARSIPPANY, NJ, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”), an emerging leader in enabling personalized medicine, today announced that it will effect a 1-for-5 reverse stock split (“Reverse Stock Split”) of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on August 27, 2026, and Interpace common stock is expected to begin trading on a split-adjusted basis on the OTCID quotation system (“OTCID”) as of the commencement of market open that same day. Interpace's ticker symbol on the OTCID will temporarily change to IDXGD for a period of 20 trading days, including the effective date. The new CUSIP number for the common stock following the Reverse Stock Split will be 46062X402.
Profitability This table compares Ethema Health and Interpace Biosciences' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ethema Health -11.61% N/A -7.48% Interpace Biosciences 65.25% 219.07% 105.05% Insider and Institutional Ownership 5.7% of Interpace Biosciences shares are held by institutional investors. 55.7% of Ethema Health shares
Q2 Revenue of $9. 1 millionQ2 Income from Continuing Operations of $0. 3 millionQ2 Thyroid volume year-over-year increase of 6%Q2 Thyroid revenue year-over-year increase of 9%Trailing twelve-month thyroid revenue of $36. 1 million, an increase of 11% on a comparable thyroid-only basis PARSIPPANY, NJ, Aug.
Q1 Revenue of $9. 0 million Q1 Income from Continuing Operations of $0. 8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.
PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update.